Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills

    Research output: Contribution to journalShort survey

    5 Scopus citations

    Abstract

    In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.

    Original languageEnglish (US)
    Pages (from-to)7-9
    Number of pages3
    JournalCancer Cell
    Volume26
    Issue number1
    DOIs
    StatePublished - Jul 14 2014

      Fingerprint

    ASJC Scopus subject areas

    • Oncology
    • Cell Biology
    • Cancer Research

    Cite this